Drugs Targeting Cough Receptors: New Therapeutic Options in Refractory or Unexplained Chronic Cough
- PMID: 38904926
- DOI: 10.1007/s40265-024-02047-y
Drugs Targeting Cough Receptors: New Therapeutic Options in Refractory or Unexplained Chronic Cough
Abstract
Refractory chronic cough is a disabling disease with very limited therapeutic options. A better understanding of cough pathophysiology has led to the development of emerging drugs targeting cough receptors. Recent strides have illuminated novel therapeutic avenues, notably centred on modulating transient receptor potential (TRP) channels, purinergic receptors, and neurokinin receptors. By modulating these receptors, the goal is to intervene in the sensory pathways that trigger cough reflexes, thereby providing relief without compromising vital protective mechanisms. These innovative pharmacotherapies hold promise for improvement of refractory chronic cough by offering improved efficacy and potentially mitigating adverse effects associated with current recommended treatments. A deeper comprehension of their precise mechanisms of action and clinical viability is imperative for optimising therapeutic interventions and elevating patient care standards in respiratory health. This review delineates the evolving landscape of drug development in this domain, emphasising the significance of these advancements in reshaping the paradigm of cough management.
© 2024. The Author(s), under exclusive licence to Springer Nature Switzerland AG.
Similar articles
-
Cough pharmacotherapy: current and future status.Expert Opin Pharmacother. 2011 Aug;12(11):1745-55. doi: 10.1517/14656566.2011.576249. Epub 2011 Apr 28. Expert Opin Pharmacother. 2011. PMID: 21524236 Review.
-
Current and emerging opioids for the treatment of chronic cough: a mini review.Expert Opin Pharmacother. 2024 Nov;25(16):2167-2175. doi: 10.1080/14656566.2024.2418983. Epub 2024 Oct 24. Expert Opin Pharmacother. 2024. PMID: 39434699 Review.
-
TRP channel antagonists as potential antitussives.Lung. 2012 Feb;190(1):11-5. doi: 10.1007/s00408-011-9322-3. Epub 2011 Oct 2. Lung. 2012. PMID: 21964632 Review.
-
The current and emerging treatment landscape for chronic cough.Am J Manag Care. 2022 Sep;28(9 Suppl):S159-S165. doi: 10.37765/ajmc.2022.89244. Am J Manag Care. 2022. PMID: 36198074
-
Targeting TRP channels for chronic cough: from bench to bedside.Naunyn Schmiedebergs Arch Pharmacol. 2015 Apr;388(4):401-20. doi: 10.1007/s00210-014-1082-1. Epub 2015 Jan 10. Naunyn Schmiedebergs Arch Pharmacol. 2015. PMID: 25572384 Review.
References
-
- Morice AH, Millqvist E, Bieksiene K, Birring SS, Dicpinigaitis P, Domingo Ribas C, Hilton Boon M, Kantar A, Lai K, McGarvey L, Rigau D, Satia I, Smith J, Song WJ, Tonia T, van den Berg JWK, van Manen MJG, Zacharasiewicz A. ERS guidelines on the diagnosis and treatment of chronic cough in adults and children. Eur Respir J. 2020;55(1):1901136. - PubMed
-
- Song WJ, Chang YS, Faruqi S, Kim JY, Kang MG, Kim S, Jo EJ, Kim MH, Plevkova J, Park HW, Cho SH, Morice AH. The global epidemiology of chronic cough in adults: a systematic review and meta-analysis. Eur Respir J. 2015;45(5):1479–81. - PubMed
-
- Meltzer EO, Zeiger RS, Dicpinigaitis P, Bernstein JA, Oppenheimer JJ, Way NA, Li VW, Boggs R, Doane MJ, Urdaneta E, Weaver JP, Schelfhout J, Fonseca E. Prevalence and burden of chronic cough in the United States. J Allergy Clin Immunol Pract. 2021;9(11):4037–44 (e4032). - PubMed
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical